Arrivent Biopharma Inc

Chart & Performance

D1W1MN

P/E

—

P/S

—

EPS

—

Div Yield, %

0.00%

Shrs. gr., 5y

—

Rev. gr., 5y

Revenues

Net income

-69m

L+87.86%

CFO

-56m

L+27.99%

Profile

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

URL

https://arrivent.com/

IPO date

Jan 26, 2024

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12
Income
Revenues
Cost of revenue	74,590	36,906
Unusual Expense (Income)
NOPBT	(74,590)	(36,906)
NOPBT Margin
Operating Taxes		(36,906)
Tax Rate
NOPAT	(74,590)
Net income	(69,333) 87.86%	(36,906) -28.49%
Dividends
Dividend yield
Proceeds from repurchase of equity		169,723
BB yield
Debt
Debt current	140	128
Long-term debt	494	22
Deferred revenue
Other long-term liabilities
Net debt	(149,755)	(163,222)
Cash flow
Cash from operating activities	(55,842)	(43,631)
CAPEX
Cash from investing activities
Cash from financing activities	42,859	169,723
FCF	(63,724)	(7,303)
Balance
Cash	150,389	163,372
Long term investments
Excess cash	150,389	163,372
Stockholders' equity	146,645	171,059
Invested Capital	4,969	11,229
ROIC
ROCE
EV
Common stock shares outstanding	31,957	33,494
Price
Market cap
EV
EBITDA	(74,590)	(36,906)
EV/EBITDA
Interest
Interest/NOPBT